Business
Confirmation of No Exposure to Silicon Valley Bank
Confirmation of No Exposure to Silicon Valley Bank.
About this update from Coiled Therapeutics Plc
[{"type":"text","content":"\n \n \n 13 March 2023\n \n \n \n \n \n \n \n \n Roquefort Therapeutics plc\n \n \n \n (\"Roquefort Therapeutics\" or the \"Company\")\n \n \n \n \n \n \n \n Confirmation of No Exposure to Silicon Valley Bank\n \n \n \n \n \n \n \n Roquefort Therapeutics (LSE:ROQ, OTCQB:ROQAF),\n the Main Market listed biotech company focused on\n developing first in class medicines in the high value and high growth oncology market\n notes the evolving situation in relation to Silicon Valley Bank (together with its UK subsidiary, collectively \"SVB\").\n \n \n \n \n \n Roquefort Therapeutics confirms that it does not have any exposure to SVB, either in relation to cash deposits, investments or debt facilities.\n \n \n \n \n \n \n -Ends-\n \n \n \n \n \n \n Enquiries:\n \n \n \n \n \n \n \n Roquefort Therapeutics plc\n \n \n \n \n \n \n \n Stephen West (Chairman) / Ajan Reginald (CEO)\n \n \n \n \n +44 (0)20 3918 8633\n \n \n \n \n \n \n \n \n \n \n Hybridan LLP (Joint Broker)\n \n \n \n Claire Louise Noyce\n \n \n \n \n \n \n \n \n Optiva Securities Limited (Joint Broker)\n \n \n \n \n \n \n \n \n +44 (0)203 764 2341\n \n \n \n \n \n \n Christian Dennis\n \n \n \n \n \n \n Buchanan (Public Relations)\n \n \n \n Ben Romney / Jamie Hooper / George Beale\n \n \n \n \n \n \n \n +44 (0)20 3411 1881\n \n \n \n \n \n \n \n \n +44 (0)20 7466 5000\n \n \n \n \n \n \n \n \n \n \n \n \n LEI: 254900P4SISIWOR9RH34\n \n \n \n \n \n \n \n \n About Roquefort Therapeutics\n \n \n \n Roquefort Therapeutics (LSE:ROQ, OTCQB:ROQAF) is a Main Market listed biotech company developing first in class drugs in the high value and high growth oncology segment prior to partnering or selling to big pharma.\n \n \n \n \n \n Since listing in March 2021, Roquefort Therapeutics has successfully acquired Lyramid Pty Limited, a leader in the development of medicines for a new therapeutic target, Midkine (a human growth factor associated with cancer progression), and most recently acquired Oncogeni Ltd, founded by Nobel Laureate Professor Sir Martin Evans, which has developed two families of innovative cell and RNA oncology medicines.\n \n \n \n \n \n Roquefort Therapeutics' portfolio consists of five fully funded, novel patent-protected pre-clinical anti-cancer medicines. &...